Dermatology Times, February 2021 (Vol. 42, No. 2)

Pediatric Teledermatology Adds Access, Cuts Wait Times

March 04, 2021

With up to 30% of pediatric health care visits involving skin complaints and fewer than 400 board-certified pediatric dermatologists in the United States, teledermatology offers a valuable tool for increasing access and cutting wait times.

Trichoscopy Aids Diagnosis, Prognosis

March 03, 2021

According to one expert at the 29th European Academy of Dermatology and Venereology Virtual Congress, trichoscopy (a dermoscopy-based diagnostic method) not only helps diagnose hair disorders and monitor treatment but also predicts treatment efficacy.

DAXI Impresses; Approaches FDA Approval

March 02, 2021

The investigational neuromodulator, evaluated in clinical trials as a treatment for glabellar lines and as a combined therapy for glabellar, dynamic forehead, and lateral canthal lines, is quickly nearing an approval by the FDA.

Legal Eagle: Can I Terminate an Employee Who Has COVID-19?

March 02, 2021

In this month's Legal Eagle column, David Goldberg, MD, JD, explains if you can terminate an employee who's COVID-19 diagnosis has negatively affected your practice and led to substantial financial losses.

Racial Differences for Preferred Acne Care

February 24, 2021

Factoring in a patient’s genetic heritage when choosing an acne care regimen could improve adherence, according to survey results that identify race-related differences in preferred sources of information and treatments for acne.

Guidelines Address COVID-19 Vaccine Concerns Related to Dermal Fillers

February 17, 2021

In the Moderna coronavirus disease 2019 (COVID-19) vaccine trials, 3 participants reported facial or lip swelling after receiving the vaccine. ASDS guidelines state that patients with a history of dermal filler injections should not void vaccinations

IL-17, IL-23 Inhibitors May Outperform Older Biologics, Oral Therapies

January 21, 2021

Several systemic therapies are currently available for the treatment of patients with moderate-to-severe psoriasis. Biologics changed the game for treatment. Continued study of and innovation in IL-17 and IL-23 inhibitors promise even better results, but clinicians need to understand each biologic in detail.

Next-Generation Therapies and Approaches Will Advance Acne Treatment

January 13, 2021

Topicals and oral antibiotics, as well as research on the skin microbiome, are paving the way for the future of acne treatment, according to a recent presentation at the 2020 ODAC Pre-Conference Inflammatory Diseases Symposium.

Expanding Line of Therapeutic Agents for Psoriasis

January 08, 2021

Several systemic therapies are available for the treatment of patients with moderate to severe psoriasis. Continued research has further elucidated the immunopathogenesis of the disease, leading to the development of novel biologic agents that are proving to more effectively and safely address moderate to severe psoriatic lesions.